PodcastIntel
Sign in Get Started Free
HCPLive
HCPLive

What the FDA's Approval of Ameluz PDT Means for Skin Cancer

Sep 16, 2026 · 0:04:10
Listen to Episode
✨ AI Summary
  • FDA approves Ameluz PDT for superficial basal cell carcinoma.
  • This is the first PDT indicated for skin cancer in the US.
  • Neal Bhatia discusses the significance of this approval for dermatology.

Guests on This Episode

NB
Neal Bhatia
researcher · 4 podcast appearances
›

More from HCPLive

HCPLive
Subcutaneous Furosemide Bioequivalent to IV, Bioavailable Across Multiple Injection Sites
Oct 12, 2026 · 0:03:18
HCPLive
Targeting Senescent Cells in Actinic Keratosis With RLS-1496
Oct 12, 2026 · 0:04:25
HCPLive
Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD
Oct 12, 2026 · 0:03:33
HCPLive
Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF
Oct 12, 2026 · 0:06:00
View all episodes →

Get AI Summaries for Every New Episode

Subscribe to HCPLive and get AI summaries, guest tracking, and email digests delivered automatically.

Sign Up Free →